Oncotarget

Research Papers:

Circulating miRNA-24 and its target YKL-40 as potential biomarkers in patients with coronary heart disease and type 2 diabetes mellitus

Xin Deng, Yaofang Liu, Mao Luo, Jian Wu, Rongyue Ma, Qin Wan and Jianbo Wu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:63038-63046. https://doi.org/10.18632/oncotarget.18593

Metrics: PDF 2203 views  |   HTML 3136 views  |   ?  


Abstract

Xin Deng1,2,*, Yaofang Liu3,*, Mao Luo1,2, Jian Wu4, Rongyue Ma5, Qin Wan6 and Jianbo Wu1,2

1Drug Discovery Research Center, Southwest Medical University, Luzhou, Sichuan, China

2Laboratory for Cardiovascular Pharmacology of Department of Pharmacology, The School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China

3Department of Gynaecology and Obstetrics, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

4Medical Research Center, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

5The Lee Woo Sing College, Chinese University of Hong Kong, Sha Tin, Hong Kong

6Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

*Xin Deng and Yaofang Liu contributed equally to this work

Correspondence to:

Jianbo Wu, email: [email protected]

Qin Wan, email: [email protected]

Keywords: biomarker, circulating miR-24, coronary heart disease, YKL-40, type 2 diabetes

Received: January 19, 2017    Accepted: May 23, 2017    Published: June 21, 2017

ABSTRACT

Type 2 diabetes mellitus (DM2) is associated with cardiovascular complications and is characterized by high levels of YKL-40, an inflammatory glycoprotein involved in endothelial dysfunction. We investigated the predictive potential of circulating miR-24 in coronary heart diseases (CHD) DM2 patients with CHD, and control subjects. Blood samples were taken from 94 subjects of both genders, and divided over three groups as follows; patients with CHD, patients with DM2 and CHD, and control subjects. Both miR-24 (using real time PCR) and routine parameters were measured. Using bioinformatic analysis and luciferase assays, we found that miR-24 has high complementarity and a high degree of species conservation with respect to the binding sites within the 3’ UTR of the YKL-40 mRNA. The expression levels of circulating miR-24, determined by quantitative real time PCR, were significantly decreased in peripheral blood of DM2-CHD and CHD patients compared with controls. Furthermore, miR-24 strongly associated with DM2-CHD, negatively correlated with YKL-40 in DM2-CHD and DM2 patients after conducting multiple regression analysis. These results provide a novel regulatory mechanism of circulating miR-24 in regulating YKL-40 levels in DM2-CHD, may serve as a biomarker for predicting patients with DM2 and CHD.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18593